Physician profile
Mitchell Gibbons
NPI 1871116210
$2,367.87
in general payments reported to CMS, 2019-2025
24 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.30 · 2024: $1,005 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $24.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.65 |
| Education | $24.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $419.81 | 2022-2025 | Sotyktu |
| Abbvie INC. | $400.95 | 2024-2025 | |
| Janssen Biotech, INC. | $196.47 | 2024-2025 | Tremfya |
| Ucb, INC. | $178.69 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $172.69 | 2024 | Dysport |
| Sun Pharmaceutical Industries INC. | $131.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $120.21 | 2024-2025 | |
| Amgen INC. | $115.80 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $99.47 | 2024-2025 | Ebglyss, Taltz |
| Organon LLC | $97.63 | 2024-2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $95.43 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $59.17 | 2025 | Dupixent |
| Agiliti Health, INC. | $43.46 | 2024 | Vbeam Perfecta |
| Leo Pharma INC. | $36.76 | 2024-2025 | Adbry |
| Convatec INC. | $29.31 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.35 | 2024 | Tremfya |
| Surgenex LLC | $23.71 | 2025 | Surgraft, Pellograft, Surmatrix |
| Kerecis Limited | $22.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Incyte Corporation | $19.90 | 2025 | Opzelura |
| Genzyme Corporation | $16.92 | 2025 | |
| Dermavant Sciences, INC. | $16.80 | 2024 | Vtama |
| Journey Medical Corporation | $15.97 | 2025 | |
| Pfizer INC. | $15.27 | 2024 | |
| Genentech USA, INC. | $13.16 | 2024 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Gibbons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.